Company Overview - SBC Medical Group Holdings Incorporated is a global franchise and provider of services for aesthetic clinics, headquartered in Irvine, California and Tokyo, Japan [6] - The company focuses on providing comprehensive management services to franchisee clinics, including advertising, staff management, booking reservations, and medical equipment procurement [6] Leadership Appointment - Shinya Inoue has been appointed as Chief Marketing Officer (CMO) effective July 1, 2025 [1][2] - Inoue will lead efforts to enhance the brand value of the group's portfolio, including Shonan Beauty Clinic, and will focus on digital innovation in marketing [2][3] Experience and Background of Shinya Inoue - Inoue has extensive experience in brand strategy and integrated marketing, having worked at companies such as P&G Japan, Eli Lilly Japan, Adobe, and KDDI [4] - He previously served as CMO at Pioneer Corporation, where he was responsible for launching the marketing organization and restructuring planning and communication areas [4] Strategic Vision - The company aims to strengthen its global competitiveness and contribute to the sustainable advancement of the medical aesthetics industry through strategic initiatives [3] - Inoue expressed commitment to making aesthetic medicine more accessible and transforming it into a more approachable part of everyday life [5]

Core Viewpoint - So-Young International Inc. is postponing the effective date for the planned change in the American depositary shares (ADS) ratio, which was initially set for June 30, 2025 [2][3]. Group 1: ADS Ratio Change - The company intends to change the ADS ratio from thirteen ADSs representing ten Class A ordinary shares to one ADS representing fifteen Class A ordinary shares [2]. - The decision to delay the ADS ratio change is due to the need for additional time to finalize preparations [2]. - An updated timeline for the ADS ratio change will be announced in the future [2]. Group 2: Impact on ADS Holders - The ADS ratio change will function similarly to a proportional reverse ADS split, with no changes to the Class A ordinary shares [3]. - ADS holders will not need to take any action; the exchange of old ADSs for new ADSs will occur automatically [3]. - Fractional new ADSs will not be issued; instead, fractional entitlements will be aggregated and sold, with net cash proceeds distributed to ADS holders [3]. Group 3: Price Expectations - Following the ADS ratio change, the ADS price is expected to increase proportionally, although there is no assurance that the post-change price will match or exceed the proportional price based on the pre-change price [4]. Group 4: Company Overview - So-Young International Inc. is a leading aesthetic treatment platform in China, connecting consumers with online services and offline treatments [5]. - The company offers access to aesthetic treatments through its online platform and branded aesthetic centers, providing curated treatment information and facilitating online reservations [5]. - With strong brand recognition and an efficient supply chain, So-Young is positioned for long-term growth in the medical aesthetic value chain [5].

Core Viewpoint - Venus Concept Inc. has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd for $20 million in cash, which is expected to enhance the company's financial condition and support strategic growth initiatives [1][2][3] Group 1: Transaction Details - The transaction is valued at $20 million, subject to customary working capital adjustments [1] - The sale includes the portfolio of hair restoration and hair transplant technologies, related equipment, services, and intellectual property, specifically for ARTAS and NeoGraft [2][3] - The transaction is anticipated to close in the third quarter of 2025, pending certain closing conditions [3] Group 2: Financial Impact - The revenue from the sale of ARTAS and NeoGraft systems, procedure kits, and warranty revenue was approximately $12.5 million in fiscal year 2024 [3] - Cash used in operations related to the hair restoration and transplant businesses totaled approximately $6.7 million in fiscal year 2024 [3] Group 3: Strategic Rationale - The CEO of Venus Concept stated that the transaction allows the company to focus on its global medical aesthetics business, which is expected to improve revenue growth and lower operating expenses [2] - Meta Healthcare Group aims to leverage the acquired technologies to expand its hair loss-related business areas and enhance R&D and manufacturing capabilities [2][5]

Core Viewpoint - So-Young International Inc. is set to report its financial results for Q1 2025 on May 16, 2025, before U.S. markets open, highlighting its position as a leading aesthetic treatment platform in China [1][2]. Group 1: Financial Reporting - The financial results for the first quarter ended March 31, 2025, will be announced before U.S. markets open on May 16, 2025 [1]. - An earnings conference call is scheduled for May 16, 2025, at 7:30 AM U.S. Eastern Time, with dial-in details provided for international and local participants [2]. Group 2: Company Overview - So-Young International Inc. is recognized as the leading aesthetic treatment platform in China, connecting consumers with both online services and offline treatments [3]. - The company offers access to aesthetic treatments through its online platform and branded aesthetic centers, providing curated treatment information and facilitating online reservations [3]. - So-Young is positioned to grow along the medical aesthetic value chain due to its strong brand recognition, digital reach, affordable treatments, and efficient supply chain [3].

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in the same period last year [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [10] - Europe was the largest revenue contributor from outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later in 2025, aiming to diversify its product offerings [6] - InMode remains committed to maintaining its workforce and not cutting costs, believing this will position the company to lead when market conditions improve [5] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company anticipates a potential reduction in operating margins by 4% to 5% due to market pressures and U.S. tariffs [13] Other Important Information - InMode completed a share repurchase program, buying back 6.95 million shares for $127 million, returning over $412 million to shareholders in the past year [7] - The company has a strong balance sheet with cash and equivalents totaling $512.9 million as of March 31, 2025 [12] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [19] Question: Guidance for Q2 and market recovery - Management expressed optimism for Q2 but noted that if results do not improve significantly, guidance may need to be lowered [30] Question: Impact of tariffs on gross margins - Management explained that current tariffs could impact gross margins by approximately 2% to 3% if they remain at 10% [56] Question: Updates on operating expenses - Management confirmed that they plan to maintain investments in sales and marketing despite macro challenges [63] Question: Pricing strategy in the current market - Management decided against raising prices due to the current market conditions, emphasizing the importance of maintaining competitiveness [70] Question: Performance in Europe compared to the U.S. - Management noted that Europe performed better in Q1 2025, attributed to management changes and pricing strategies [83]

Financial Data and Key Metrics Changes - InMode generated total revenue of $77.9 million in Q1 2025, a decrease of 3% compared to Q1 2024 [8] - GAAP gross margin was 78% in Q1 2025, down from 80% in Q1 2024 [8] - Non-GAAP diluted earnings per share were $0.31, compared to $0.32 in Q1 2024 [12] - The company ended the quarter with cash and cash equivalents of $512.9 million [12] Business Line Data and Key Metrics Changes - Minimally invasive platforms accounted for 87% of total revenues in Q1 2025 [9] - Sales and marketing expenses decreased slightly to $39.7 million in Q1 2025 from $39.8 million in Q1 2024 [11] Market Data and Key Metrics Changes - International sales accounted for $38 million or 49% of total sales, a 1% increase compared to Q1 2024 [9] - Europe was the largest revenue contributor from outside the U.S., achieving record sales [10] Company Strategy and Development Direction - The company plans to unveil a new platform for the wellness market later this year, reflecting its strategy to diversify offerings [6] - InMode has committed to not reducing its workforce and aims to lead the industry during the market rebound [6] Management's Comments on Operating Environment and Future Outlook - Management noted ongoing macroeconomic uncertainty and soft consumer demand affecting the medical aesthetic market [4] - The company anticipates a potential reduction in operating margins by 4% to 5% due to market pressures and U.S. tariffs [13] - Management remains optimistic about a market recovery, contingent on Q2 performance [30] Other Important Information - InMode returned over $412 million to shareholders through share repurchases over the past twelve months, representing approximately 27% of total capital [7] - The company has not yet hired a new President for the U.S. and is currently led by the acting President [66] Q&A Session Summary Question: Follow-up on product mix dynamics - Management indicated that the slowdown began in mid-2023 due to rising interest rates and decreased consumer confidence, impacting capital equipment purchases [20][21] Question: Guidance for Q2 and market trends - Management expects Q2 to be stronger than Q1, but if results do not improve, guidance may need to be lowered [31][40] Question: Impact of tariffs on guidance - Tariffs are expected to impact gross margins by approximately 2% to 3% if they remain at 10% [57][79] Question: Updates on operating expenses - The company plans to maintain its investment in sales and marketing despite macro challenges, which may impact profitability [65] Question: Pricing strategy in the current market - Management decided not to raise prices due to the current market conditions, despite tariff impacts [70][90] Question: Performance in Europe compared to the U.S. - Europe has shown better performance due to management changes and pricing strategies, although credit conditions are tightening [83]

Financial Data and Key Metrics Changes - In Q4 2024, total revenue was RMB 369.2 million, a decrease of 5.5% year-over-year, primarily due to a decline in revenue from So-Young Prime [23] - Net loss attributable to So-Young was RMB 607.6 million, compared to a net income of RMB 17.5 million in the same period last year [27] - Non-GAAP net loss was RMB 53.2 million, compared to a non-GAAP net income of RMB 35.7 million in Q4 2023 [27] - For the full year 2024, total revenues were RMB 1.47 billion, down 2.1% year-over-year [28] Business Line Data and Key Metrics Changes - Revenue from aesthetic treatment services surged to RMB 81.3 million, up 701.6% year-over-year, driven by the expansion of the aesthetic center business [23] - Sales of medical products and maintenance services were RMB 86.2 million, down 15.2% year-over-year, primarily due to a decrease in order volume for medical equipment [23] - Cost of aesthetic treatment services was RMB 65.2 million, up 702.3% year-over-year, reflecting the expansion of the aesthetic center business [24] Market Data and Key Metrics Changes - Total GMV for verified medical aesthetic services reached RMB 356.6 million, up 3% sequentially [17] - The total number of verified paid aesthetic treatments surpassed 81,500, with over 38,000 verified paid visits recorded [10][11] - The total number of active users exceeded 39,500, indicating strong brand appeal and market demand [11] Company Strategy and Development Direction - The company is focused on vertical integration within the aesthetic medical industry, leveraging its user base and supply chain capabilities to drive growth [7][32] - Plans to deepen presence in core cities and replicate successful aesthetic centers to expand the network further [14] - The company aims to establish a leading light medical aesthetic chain with over 1,000 locations in China, which currently has a low penetration rate of chain clinics [51][52] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term strategy, emphasizing the importance of establishing a robust aesthetic center network and improving financial performance [32] - The company anticipates steady improvement in financial performance as market conditions stabilize and aesthetic center businesses expand [32] - Management acknowledged that while near-term profitability may be impacted by expansion efforts, the focus remains on sustainable high-quality growth [66] Other Important Information - The company recorded a one-time goodwill impairment charge of RMB 540 million for its subsidiary, impacting the bottom line [7] - Customer satisfaction remains high at 4.98 out of 5, indicating strong service quality [10] Q&A Session Summary Question: What are the latest developments in merchant support during the industry consolidation period? - Management highlighted the importance of differentiators for specialized medical aesthetic institutions to maintain pricing power and market presence [36][37] Question: How does the company adapt its strategies for centers at different stages of development? - Management explained the implementation of differentiated operational strategies for aesthetic centers in various phases to optimize performance and enhance brand influence [44][46] Question: Can the aesthetic center business maintain growth? - Management indicated that the aesthetic center network has significant growth potential, with low market penetration of chain clinics in China [51][52] Question: What is the strategy for the upstream business? - Management discussed the integration of Miracle Laser into the upstream business, focusing on product innovation and enhancing supply chain capabilities [58][60] Question: Could management share more insights into the company's financial outlook? - Management reiterated the commitment to sustainable growth through vertical integration and maintaining a balance between growth and profitability [66]